Cara J Westmark

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. Westmark C. What's hAPPening at synapses? The role of amyloid ?-protein precursor and ?-amyloid in neurological disorders. Mol Psychiatry. 2013;18:425-34 pubmed publisher
    ....
  2. Westmark C, Westmark P, Malter J. MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int J Clin Exp Pathol. 2009;3:56-68 pubmed
    ..These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients. ..
  3. Westmark C, Westmark P, O Riordan K, Ray B, Hervey C, Salamat M, et al. Reversal of fragile X phenotypes by manipulation of A?PP/A? levels in Fmr1KO mice. PLoS ONE. 2011;6:e26549 pubmed publisher
    ..Evolving therapies directed at reducing A? in AD may be applicable to FXS and A? may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy...
  4. Westmark C, Malter J. The regulation of A?PP expression by RNA-binding proteins. Ageing Res Rev. 2012;11:450-9 pubmed publisher
    ....

Locale

Detail Information

Publications4

  1. Westmark C. What's hAPPening at synapses? The role of amyloid ?-protein precursor and ?-amyloid in neurological disorders. Mol Psychiatry. 2013;18:425-34 pubmed publisher
    ....
  2. Westmark C, Westmark P, Malter J. MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int J Clin Exp Pathol. 2009;3:56-68 pubmed
    ..These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients. ..
  3. Westmark C, Westmark P, O Riordan K, Ray B, Hervey C, Salamat M, et al. Reversal of fragile X phenotypes by manipulation of A?PP/A? levels in Fmr1KO mice. PLoS ONE. 2011;6:e26549 pubmed publisher
    ..Evolving therapies directed at reducing A? in AD may be applicable to FXS and A? may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy...
  4. Westmark C, Malter J. The regulation of A?PP expression by RNA-binding proteins. Ageing Res Rev. 2012;11:450-9 pubmed publisher
    ....